Facebook
Twitter
Telegram
Report an ErrorAlpine Immune Sciences Balance Sheet 2011-2024 | ALPN
Annual Balance Sheet Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-63.9 M | -24.8 M | -11.2 M | -6.51 M | -2.97 M | -24.2 M | -25 M | -27.8 M | 14.2 M | - | - | |
Long Term Debt |
- | 3.38 M | 7.6 M | 4.51 M | 2.16 M | 4.04 M | - | - | - | 13.3 M | - | - |
Long Term Debt Current |
756 K | 617 K | 655 K | 418 K | 2.05 M | 995 K | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 15.9 M | 2.16 M | 4.41 M | - | - | 41.9 M | 91.4 M | - | - |
Total Current Liabilities |
58 M | 69.8 M | 41.2 M | 8.68 M | 8.13 M | 1.9 M | 6.5 M | 4.42 M | - | - | - | - |
Total Liabilities |
107 M | 135 M | 81.9 M | 24.6 M | 10.3 M | 6.3 M | 6.5 M | 4.42 M | 44.3 M | 95.4 M | - | - |
Deferred Revenue |
35.6 M | 51.8 M | 31.6 M | 1.44 M | - | 277 K | - | - | - | - | - | - |
Retained Earnings |
-224 M | -166 M | -116 M | -87.9 M | -46.1 M | -9.38 M | -180 M | -149 M | -126 M | -111 M | - | - |
Total Assets |
287 M | 256 M | 144 M | 54.1 M | 54.9 M | 85.2 M | 61.9 M | 87.9 M | 28.5 M | 4.13 M | - | - |
Cash and Cash Equivalents |
13.4 M | 67.9 M | 35.2 M | 16.1 M | 10.7 M | 8 M | 24.2 M | 25 M | 27.8 M | 1.1 M | - | - |
Book Value |
179 M | 121 M | 62.2 M | 29.5 M | 44.6 M | 78.9 M | 55.4 M | 83.5 M | -15.8 M | -91.3 M | - | - |
Total Shareholders Equity |
179 M | 121 M | 62.2 M | 29.5 M | 44.6 M | 78.9 M | 55.4 M | 83.5 M | -15.8 M | -91.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
8.7 M | 9 M | 9.29 M | 9.56 M | 1.6 M | 10.1 M | - | 1.02 M | 2.21 M | 3.38 M | 4.55 M | 5.71 M | 6.46 M | 7.6 M | 7.6 M | 7.6 M | 7.6 M | 4.51 M | 4.51 M | 4.51 M | 4.51 M | 2.16 M | 2.16 M | 2.16 M | 2.16 M | 4.04 M | 4.04 M | 4.04 M | 4.04 M | 113 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
40.9 M | 51.9 M | 78.9 M | 83.4 M | 92.6 M | 107 M | 110 M | 116 M | 119 M | 135 M | 111 M | 116 M | 76.7 M | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 2.52 M | 2.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
10.2 M | 16.3 M | 30.1 M | 37.3 M | 40.4 M | 35.6 M | 46.2 M | 42.9 M | 51.8 M | 51.8 M | 48.1 M | 49 M | 34.5 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 1.44 M | 1.44 M | 1.44 M | 1.44 M | - | - | - | 240 K | 277 K | 405 K | 277 K | - | 2.01 M | 2.01 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-274 M | -256 M | -262 M | -250 M | -237 M | -224 M | -205 M | -192 M | -174 M | -166 M | -151 M | -138 M | -127 M | -116 M | -116 M | -116 M | -116 M | -87.9 M | -87.9 M | -87.9 M | -87.9 M | -46.1 M | -46.1 M | -46.1 M | -46.1 M | -9.38 M | -9.38 M | -9.38 M | -9.38 M | -1.6 M | -1.6 M | -180 M | -180 M | -149 M | -149 M | -149 M | -149 M | -126 M | -126 M | -126 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
374 M | 380 M | 241 M | 253 M | 262 M | 287 M | 292 M | 216 M | 234 M | 256 M | 233 M | 160 M | 130 M | 144 M | 144 M | 144 M | 144 M | 54.1 M | 54.1 M | 54.1 M | 54.1 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 85.2 M | 85.2 M | 85.2 M | 85.2 M | 12.6 M | 12.6 M | 61.9 M | 61.9 M | 87.9 M | 87.9 M | 87.9 M | 87.9 M | 28.5 M | 28.5 M | 28.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
33 M | 43.9 M | 19 M | 34.1 M | 14.7 M | 13.4 M | 127 M | 24.6 M | 35.1 M | 67.9 M | 76.4 M | 19.1 M | 12.6 M | 35 M | 35 M | 35 M | 35 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 8 M | 8 M | 8 M | 8 M | 11.8 M | 11.8 M | 24.2 M | 24.2 M | 25 M | 25 M | 25 M | 25 M | 27.8 M | 27.8 M | 27.8 M | - | 1.1 M | - | - | - | 4.7 M | - | - | - | - | - | - | - |
Book Value |
333 M | 328 M | 162 M | 169 M | 170 M | 179 M | 182 M | 99.5 M | 115 M | 121 M | 123 M | 43.8 M | 53.3 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 44.6 M | 44.6 M | 44.6 M | 44.6 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | 10.1 M | 10.1 M | 61.9 M | 61.9 M | 87.9 M | 87.9 M | 87.9 M | 87.9 M | 28.5 M | 28.5 M | 28.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
333 M | 328 M | 162 M | 169 M | 170 M | 179 M | 182 M | 99.5 M | 115 M | 121 M | 123 M | 43.8 M | 53.3 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 44.6 M | 44.6 M | 44.6 M | 44.6 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | -1.46 M | -1.46 M | 55.4 M | 55.4 M | 83.5 M | 83.5 M | 83.5 M | 83.5 M | -15.8 M | -15.8 M | -15.8 M | - | -91.3 M | - | - | - | -75.2 M | - | - | - | - | - | - | - |
All numbers in USD currency